Answers are grounded in this paper and cite their sources.
Demonstrates immunotherapy efficacy in breast cancer, highlighting new treatment strategies.
Breast cancer is characterized by a profoundly immunosuppressive tumor microenvironment (TME), which severely limits therapeutic efficacy and immune activation. Here, we develop a zinc-iron bimetallic MOF-integrated thermosensitive hydrogel (ZF-Gel) for in situ breast cancer immunotherapy via ferroptosis-induced cGAS-STING activation. Upon intratumoral injection, ZF-Gel undergoes rapid temperature-triggered sol-gel transition, forming a stable intratumoral depot that enables sustained local retention. Mechanistically, the Zn/Fe bimetallic MOF induces oxidative stress and lipid peroxidation, triggering ferroptosis. Ferroptosis-associated damage signals, together with Zn2+-mediated regulation, activate the cGAS–STING pathway, leading to IRF3 phosphorylation and downstream immune gene expression, thereby coupling tumor cell death with innate immune sensing and adaptive immune activation. In vitro, ZF-Gel exhibits pronounced antiproliferative effects against breast cancer cells. This work establishes a mechanism-driven hydrogel-MOF platform that integrates local retention, regulated cell death, and innate–adaptive immune crosstalk, offering a promising strategy for immunologically cold breast tumors.
No takes yet. Share an insight, caveat, or question.
Zhan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: